Swissmedic, the Swiss Agency for Therapeutic Products, has authorized the COVID-19 Moderna Vaccine in Switzerland.
The authorization is given according to the ordinary approvals procedure and is based on a rolling submission of data and the totality of scientific evidence shared by Moderna, including a data analysis from the pivotal Phase 3 clinical study announced on November 30.
“Having our COVID-19 Vaccine Moderna authorized in Switzerland is an important milestone for us,” said Stéphane Bancel, CEO of Moderna.
“Switzerland has played a critical role in Moderna’s history since our early days and it means a lot to us that we can now provide a highly effective vaccine to help protect the citizens of Switzerland.”
The Swiss Federal Government has secured 7.5 million doses of the COVID-19 Vaccine Moderna. Following the authorisation, the first deliveries are beginning this week.
Moderna has also received authorization for its COVID-19 vaccine from regulatory authorities in the United States, Canada, Israel, the European Union and the United Kingdom.
Additional authorizations are currently under review in other countries and by the World Health Organization.